Source-grounded facts extracted from OMEROS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.
“Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET”
OMEROS CORP completed a disposition involving Novo Nordisk Health Care AG for upfront cash payment of $240.0 million at closing, plus potential milestone payments up to $1.81 billion (development and sales-based milestones) and tiered roy (closed 2025-11-25).
“development and commercialization activities of both companies (the “Transaction”). At the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in”
David J. Borges was appointed as Vice President, Finance, Chief Accounting Officer and Treasurer at OMEROS CORP.
“On June 10, 2024, the Company’s Board of Directors appointed David J. Borges as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024 (the “Effective Date”), and designated him as the Company’s principal financial officer and principal accounting officer as of the Effective Date.”
Michael A. Jacobsen retired as Vice President, Finance, Chief Accounting Officer and Treasurer at OMEROS CORP.
“On June 10, 2024, Michael A. Jacobsen informed the Board of Directors of Omeros Corporation (“Omeros” or the “Company”) of his intention to retire from his positions as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024.”
OMEROS CORP reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, EPS $0.63 per share.
“Omeros Corporation Reports First Quarter 2024 Financial Results”
OMEROS CORP reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, EPS net loss of $117.8 million, or $1.88 per share.
“Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: ● Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter. ● For the year ended December 31, 2023, net loss was $117.8 million, or $1.88 per share, compared to net income of $47.4 million, or $0.76 per share, in the prior year.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.